TY - JOUR
T1 - Antipsychotic-induced brain atrophy
T2 - Is lithium the answer in bipolar disorder?
AU - Elangovan, Sagar
AU - Bastiampillai, Tarun
AU - Kanigere, Milanduth
AU - Kulkarni, Sandip
AU - Tibrewal, Prashant
PY - 2019/9/1
Y1 - 2019/9/1
N2 - We note the recent debate piece (Bastiampillai et al., 2018) highlighting concerns about the potential implications of prescribing antipsychotic medication in paediatric populations, due to the potential risks of antipsychotic-induced brain atrophy. Worldwide antipsychotic medications are increasingly being prescribed for the maintenance treatment of bipolar affective disorder (BPAD) in preference to mood-stabilising medication like lithium. Lithium use is declining despite being the gold standard treatment for the maintenance phase of BPAD.
AB - We note the recent debate piece (Bastiampillai et al., 2018) highlighting concerns about the potential implications of prescribing antipsychotic medication in paediatric populations, due to the potential risks of antipsychotic-induced brain atrophy. Worldwide antipsychotic medications are increasingly being prescribed for the maintenance treatment of bipolar affective disorder (BPAD) in preference to mood-stabilising medication like lithium. Lithium use is declining despite being the gold standard treatment for the maintenance phase of BPAD.
KW - prescribing antipsychotic medication
KW - antipsychotic-induced brain atrophy
KW - bipolar affective disorder (BPAD)
KW - lithium
KW - maintenace phase of BPAD
UR - http://www.scopus.com/inward/record.url?scp=85070249420&partnerID=8YFLogxK
U2 - 10.1177/0004867419865393
DO - 10.1177/0004867419865393
M3 - Letter
C2 - 31339338
AN - SCOPUS:85070249420
SN - 0004-8674
VL - 53
SP - 925
EP - 926
JO - Australian and New Zealand Journal of Psychiatry
JF - Australian and New Zealand Journal of Psychiatry
IS - 9
ER -